<DOC>
	<DOCNO>NCT02614027</DOCNO>
	<brief_summary>To evaluate prevalence lipodystrophy syndrome patient receive currently available antiretroviral drug , prevalence associate metabolic syndrome HIV-infected patient previous diagnosis lipodystrophy syndrome , accord severity fat accumulation antiretroviral drug use .</brief_summary>
	<brief_title>Prevalence Lipodystrophy Syndrome Its Role Cause Metabolic Disturbances</brief_title>
	<detailed_description>Cross-sectional evaluation two group patient : - patient receive currently available drug , order determine change fat accumulation successive dual X-ray absorptiometry ( DXA ) determination - patient previous lipodystrophy syndrome , evaluate questionnaire ( HOPS ) total body dual X-ray absorptiometry ( DXA ) , order determine prevalence hypertension , low high density lipoprotein ( HDL ) -cholesterol , glucose disturbance ( insulin resistance diabetes ) , fat accumulation ( waist circumference ) hypertriglyceridemia . The prevalence Metabolic syndrome evaluate accord different definition ( IDF , NCEP-ATP III , WHO ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<criteria>HIV infection Older 18 year Receiving first second antiretroviral regimen Previous evaluation classification lipodystrophy syndrome Pregnancy Diagnosis hypothyroidism , Cushing 's syndrome prolong intake corticosteroid hormone inclusion Patients receive antiretroviral drug know produce fat disturbance ( lipodystrophy prevalence objective )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>